期刊文献+

拜新同治疗不同程度高血压临床疗效观察 被引量:2

下载PDF
导出
摘要 目的:评价拜新同对轻中度高血压临床疗效及安全性。方法:对本院2010年6月~2011年6月200例高血压患者,停服其他降压药2周以上,口服拜新同,1次/d,6周为1个疗程,观察其临床疗效及安全性。结果:200例患者经过6周治疗后,显效120例,有效60例,无效20例,总有效率为90%,未出现不良反应。结论:拜新同是一种长效钙通道阻断剂,拜新同能持续有效控制血压,不良反应少,安全性高,可以作为治疗轻中度高血压的首选药。
出处 《北方药学》 2013年第1期28-29,共2页 Journal of North Pharmacy
  • 相关文献

参考文献2

二级参考文献6

  • 1[1]Brown MJ,Palmer CR,Castaigne A,et al. Morbidity and morta-lity in patients randomized to duble-blind treatment with a long-acting calcium-channal blocker or diuretic in the Internation nifedipine once-daily study:intervention as a goal in hypertension treatment(INSIGHT).Lancet, 2000,356(9227):366~372.
  • 2[2]Brown MJ, Castaigne A, de Leeuw PW, et al. Study population and treatment titration in the internation nifedipine GITS study:intervention as a goal in hypertension treatment(INSIGHT). J Hypertens, 1998,16(12PT2):2113~2116.
  • 3[3]krakoff LR. Effectiveness of nefidipine gastrointestinal therapeutic system for treatment of hypertension: results of the MATH trial. J Cardiovasc Pharmacol,1993,21Supp12:S14~17.
  • 4[4]Toal CB, Mahon WA, Barnes C, et al. Nefidipine gastrointestinal therapeutic system (GITS) for treatment of hypertensive patients in a primary care setting:results of the extended release adalat canadian trial(EXACT). Clin Ther, 1997,19(5):925~935.
  • 5[5]Myers MG. Difydropyridine calcium antagonists and the trough; peak ratio:focus on adverse effects.J Hypertens Suppl, 1994,12(8): 73~76.
  • 6[6]Kirby BJ, Kitchin NR. A comparison of the effects of two nefidipine release preparations of nefidipine - nefidipine retard 10mg twice daily and nefidine GITS 20mg once daily in treatment of mild to moderate hypertension. Int J Clin Pract, 1999,53(5): 339~343.

共引文献33

同被引文献19

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部